Sun Pharmaceutical Industries has received US FDA approval for an ANDA to market a generic version of Optivar, azelastine ophthalmic solution, 0.05 per cent.
This sterile azelastine hydrochloride ophthalmic solution is therapeutically equivalent to Optivar ophthalmic solution, 0.05 per cent from Medpointe Pharmaceuticals which has annual sales of approximately US$ 50 million in the US.
Azelastin is a selective antihistamine for the treatment of the itching of the eyes associated with allergic conjunctivitis.